AIAMGENE reads the whole genome of the amniotic stem cells saved at birth, and turns it into a living genomic twin — helping predict, care for, and monitor your child's development, from the very first day.
The amniotic stem cells saved at your child's birth are biologically age zero — never touched by aging, illness, or pollution. They carry the longest telomeres and the cleanest genome a person will ever have. Until now they were discarded at delivery, or banked and left unused. AIAMGENE reads that genome once, and turns it into care that lasts a lifetime.
Artificial intelligence, amniotic-membrane stem cells, and the human genome — brought together into a single platform that learns and cares over time.
A multi-agent engine learns each child's biology, decides when and how care is delivered, and reads how the body responds.
Age-zero amniotic stem cells, and the secretome cultured from them, nurture the body's own capacity to grow and repair.
One whole-genome reading at birth reveals individual susceptibility early — so care can begin before, not after.
Genome predicts. Secretome cares. RNA confirms. Each cycle teaches the next — so the platform grows more precise the longer it's part of a child's life.
Whole-genome sequencing reads about 3 billion base pairs and some 20,000 genes to map early susceptibility across neurodevelopment, growth, and medication response.
Matched to what's predicted, amniotic stem-cell secretome is delivered gently and early through a baby-friendly nasal mist — care that supports healthy development.
RNA expression is tracked to see how the body is responding at the molecular level — often before anything shows on the surface.
Every reading becomes a genomic avatar that grows alongside your child. Results appear in plain language and a simple traffic-light — a score is a vulnerability, never a diagnosis — so families understand, not worry.
Our device concept delivers stem-cell secretome the way a child naturally breathes. Shaped as a playful nursery mobile, a soft character gently descends and releases a fine nasal mist on a timer — turning daily care into play.
Because amniotic stem cells carry HLA-G, they have very low immunogenicity — so they hold potential not only for the child, but for the parents, grandparents, and siblings who share their genes. And unlike cord blood, typically used once, cultured cells can be re-used and re-analyzed at every stage of growth.
AIAMGENE is built on adult stem-cell science that is recognized, regulated, and clinically applied across the world.
A multi-agent AI, tuned for Korean genomes. Dedicated agents for neurodevelopment, rare disease, medication, and growth cross-validate over a Korean-population knowledge graph — linking variant, gene, pathway, and phenotype to filter meaningful signal from millions of variants.
Our initial research explores early neurodevelopmental support, with mouse-model studies evaluating amniotic stem-cell culture medium. AIAMGENE is designed to extend to more areas of care as the evidence grows.
We are building an intelligent platform to care for the next generation. Learn more, or partner with us.